JP2009518406A - エストロゲン癌療法 - Google Patents

エストロゲン癌療法 Download PDF

Info

Publication number
JP2009518406A
JP2009518406A JP2008544422A JP2008544422A JP2009518406A JP 2009518406 A JP2009518406 A JP 2009518406A JP 2008544422 A JP2008544422 A JP 2008544422A JP 2008544422 A JP2008544422 A JP 2008544422A JP 2009518406 A JP2009518406 A JP 2009518406A
Authority
JP
Japan
Prior art keywords
estrogen
cancer
patient
paclitaxel
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008544422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009518406A5 (enExample
Inventor
シンガー，ジャック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Therapeutics inc
Original Assignee
Cell Therapeutics inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37891993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2009518406(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cell Therapeutics inc filed Critical Cell Therapeutics inc
Publication of JP2009518406A publication Critical patent/JP2009518406A/ja
Publication of JP2009518406A5 publication Critical patent/JP2009518406A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008544422A 2005-12-06 2006-12-05 エストロゲン癌療法 Pending JP2009518406A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74272505P 2005-12-06 2005-12-06
US81422106P 2006-06-16 2006-06-16
PCT/US2006/046281 WO2007067498A1 (en) 2005-12-06 2006-12-05 Estrogen cancer therapy

Publications (2)

Publication Number Publication Date
JP2009518406A true JP2009518406A (ja) 2009-05-07
JP2009518406A5 JP2009518406A5 (enExample) 2010-01-28

Family

ID=37891993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008544422A Pending JP2009518406A (ja) 2005-12-06 2006-12-05 エストロゲン癌療法

Country Status (9)

Country Link
US (1) US20070167349A1 (enExample)
EP (1) EP1957065A1 (enExample)
JP (1) JP2009518406A (enExample)
KR (1) KR20080074202A (enExample)
CA (1) CA2630553A1 (enExample)
PE (1) PE20070701A1 (enExample)
RU (1) RU2008127309A (enExample)
TW (1) TWI322010B (enExample)
WO (1) WO2007067498A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014250A1 (en) * 2008-08-01 2010-02-04 Cell Therapeutics, Inc. Prediction of cancer therapy based on cathespin b levels
WO2010014249A1 (en) * 2008-08-01 2010-02-04 Cell Therapeutics, Inc. Cancer therapy comprising estrogen inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537328A (ja) * 1999-02-26 2002-11-05 ナプロ バイオセラピューティクス，インコーポレイテッド ホルモン感受性癌の治療レジメ
JP2003511423A (ja) * 1999-10-12 2003-03-25 セル・セラピューティックス・インコーポレーテッド ポリグルタメート−治療薬コンジュゲートの製造

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
GB9120653D0 (en) * 1991-09-27 1991-11-06 Procter & Gamble Dispensing agent
US5731316A (en) * 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537328A (ja) * 1999-02-26 2002-11-05 ナプロ バイオセラピューティクス，インコーポレイテッド ホルモン感受性癌の治療レジメ
JP2003511423A (ja) * 1999-10-12 2003-03-25 セル・セラピューティックス・インコーポレーテッド ポリグルタメート−治療薬コンジュゲートの製造

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN5008022407; ＭＡＮ　Ｍ: ＩＤＲＵＧＳ Ｖ８　Ｎ９, 20050823, Ｐ７３９-７５４ *

Also Published As

Publication number Publication date
TWI322010B (en) 2010-03-21
TW200803836A (en) 2008-01-16
CA2630553A1 (en) 2007-06-14
PE20070701A1 (es) 2007-07-20
WO2007067498A1 (en) 2007-06-14
RU2008127309A (ru) 2010-01-20
KR20080074202A (ko) 2008-08-12
US20070167349A1 (en) 2007-07-19
EP1957065A1 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
US20230372499A1 (en) Dendrimer compositions and methods for drug delivery
Zhu et al. PEGylated PAMAM dendrimer-doxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation
Cerqueira et al. Microglia response and in vivo therapeutic potential of methylprednisolone‐loaded dendrimer nanoparticles in spinal cord injury
KR101972303B1 (ko) 단백질-중합체-약물 접합체
CN103002919B (zh) 纳米聚合物对免疫调节剂的肿瘤靶向递送
AU2018368520B2 (en) Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of Cathepsin B
Yang et al. PTN-PTPRZ1 signaling axis blocking mediates tumor microenvironment remodeling for enhanced glioblastoma treatment
MX2012005423A (es) Anticuerpos anti-integrina unidos a nanoparticulas cargadas con agentes quimioterapeuticos.
US20180214563A1 (en) Immunostimulatory nanocarrier
Poudel et al. Combination chemotherapeutic and immune-therapeutic anticancer approach via anti-PD-L1 antibody conjugated albumin nanoparticles
KR20190053206A (ko) 혈소판 조성물 및 치료제의 전달 방법
AU2018342909A1 (en) Castration resistant prostate cancer
Jin et al. Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F (ab′) 2 for hepatocellular carcinoma
WO2023122599A1 (en) Glycosylated dendrimers for targeted intracellular delivery
Peng et al. Legumain protease-activated tuftsin-functionalized nanoparticles for dual-targeting TAMs and cancer chemotherapy
KR20240123233A (ko) 캄토테신-iRGD 접합체를 포함하는 암세포 표적화 약물전달체 및 이의 제조방법
Cillari et al. Harnessing sulfur-doped carbon nanodots conjugated with IDO inhibitors act as a dual-mode breast cancer immunotherapy
US20230381183A1 (en) USE OF FOLIC ACID AND FOLATE MODIFICATION IN INDUCING B-CELL IMMUNE TOLERANCE AND TARGETING mIgM-POSITIVELY-EXPRESSED B-CELL LYMPHOMA
Sun et al. A potential platform of combining sialic acid derivative-modified paclitaxel cationic liposomes with antibody–drug conjugates inspires robust tumor-specific immunological memory in solid tumors
Zhang et al. Microenvironment-activatable cascaded responsive carbonized polymer dots as a theranostic platform for precise rapamycin delivery to potentiate the synergy of chemotherapy and γδ T cells-mediated immunotherapy against tumor
JP2009518406A (ja) エストロゲン癌療法
KR102552061B1 (ko) 이중표적 지질-폴리머 하이브리드 나노입자
MX2008007281A (en) Estrogen cancer therapy
Collyer et al. Selective Delivery of Clinically Approved Tubulin Binding Agents through Covalent Conjugation to an Active Targeting Moiety
WO2025166213A1 (en) Treatment of head and neck cancer with pharmaceutical composition comprising nanoparticles containing taxane

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120622

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130423